SYSTEMIC DRUGS IN THE TREATMENT OF DERMATOPHYTOSES

This review will discuss important and controversial features of systemic drugs currently available for the treatment of dermatophytoses (Table 1). A discussion will follow of new pharmaceutical agents, which are not yet available in the United States, and will consider the difficult and intriguing question of how these new agents will impact on the treatment of dermatophyte infections after their approval for dermatologic use.'"' H3C0 OCH3 0 OCH.

[1]  D. Roberts.  Itraconazole in dermatology. , 1992, The Journal of dermatological treatment.

[2]  F. Rongioletti,et al.  Treatment of onychomycosis with itraconazole. , 1992, The Journal of dermatological treatment.

[3]  A. Notowicz,et al.  Itraconazole versus griseofulvin. A double-blind comparison in patients with tinea corporis and tinea cruris , 1992 .

[4]  G. Medoff,et al.  Systemic fungal infections: an overview. , 1991, Hospital practice.

[5]  R. Hay.  Antifungal drugs in dermatology. , 1990, Seminars in dermatology.

[6]  N. Zaias.  Management of onychomycosis with oral terbinafine. , 1990, Journal of the American Academy of Dermatology.

[7]  J. Birnbaum.  Pharmacology of the allylamines. , 1990, Journal of the American Academy of Dermatology.

[8]  N. Zaias,et al.  Treatment of chronic moccasin-type tinea pedis with terbinafine: a double-blind, placebo-controlled trial. , 1990, Journal of the American Academy of Dermatology.

[9]  R. Savin.  Oral terbinafine versus griseofulvin in the treatment of moccasin-type tinea pedis. , 1990, Journal of the American Academy of Dermatology.

[10]  F. Flowers,et al.  Griseofulvin: A New Look at an Old Drug , 1990, DICP : the annals of pharmacotherapy.

[11]  P. Jacobs.  Treatment of fungal skin infections: state of the art. , 1990, Journal of the American Academy of Dermatology.

[12]  R. Hay,et al.  Itraconazole in the management of chronic dermatophytosis. , 1990, Journal of the American Academy of Dermatology.

[13]  A. Bonifaz,et al.  Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules. , 1990, Journal of the American Academy of Dermatology.

[14]  J. Galgiani.  Fluconazole, a new antifungal agent. , 1990, Annals of internal medicine.

[15]  P. Davey.  New antiviral and antifungal drugs. , 1990, BMJ.

[16]  J. Cleary,et al.  Imidazoles and Triazoles in Antifungal Therapy , 1990, DICP : the annals of pharmacotherapy.

[17]  E. Svejgaard,et al.  Itraconazole in onychomycosis. Open and double-blind studies. , 1990, Acta dermato-venereologica.

[18]  T. Jones,et al.  Clinical efficacy and tolerability of terbinafine (Lamisil)—a new topical and systemic fungicidal drug for treatment of dermatomycoses , 1989, Clinical and experimental dermatology.

[19]  N. Ryder.  The mechanism of action of terbinafine , 1989, Clinical and experimental dermatology.

[20]  R. Savin.  Successful treatment of chronic tinea pedis (moccasin type) with terbinafine (Lamisil) , 1989, Clinical and experimental dermatology.

[21]  N. Zaias,et al.  The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine , 1989, Clinical and experimental dermatology.

[22]  J. Jensen,et al.  Clinical pharmacokinetics of terbinafine (Lamisil) , 1989, Clinical and experimental dermatology.

[23]  S. Kagawa.  Clinical efficacy of terbinafine in 629 Japanese patients with dermatomycosis , 1989, Clinical and experimental dermatology.

[24]  S. Clissold,et al.  Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. , 1989, Drugs.

[25]  R. Hay.  New Oral Treatments for Dermatophytosis , 1988, Annals of the New York Academy of Sciences.

[26]  B. Dupont,et al.  Fluconazole for the Treatment of Fungal Diseases in Immunosuppressed Patients , 1988, Annals of the New York Academy of Sciences.

[27]  R. Hay,et al.  An evaluation of itraconazole in the management of onychomycosis , 1988, The British journal of dermatology.

[28]  R. Fromtling.  Overview of medically important antifungal azole derivatives , 1988, Clinical Microbiology Reviews.

[29]  H. Degreef,et al.  Pharmacokinetic profile of orally administered itraconazole in human skin. , 1988, Journal of the American Academy of Dermatology.

[30]  David W. Warnock,et al.  Clinical Pharmacokinetics of Ketoconazole , 1988, Clinical pharmacokinetics.

[31]  J. Lesher,et al.  Antifungal agents in dermatology. , 1987, Journal of the American Academy of Dermatology.

[32]  S. Sherlock,et al.  Hepatic reactions associated with ketoconazole in the United Kingdom. , 1987, British medical journal.

[33]  R. Hay,et al.  First International Symposium on Itraconazole: A Summary , 1987 .

[34]  J. Rippon.  A new era in antimycotic agents. , 1986, Archives of dermatology.

[35]  R. Hay.  The current status of antimycotics in the treatment of local mycoses. , 1986, Acta dermato-venereologica. Supplementum.

[36]  W. Griffiths,et al.  A comparative double blind study of ketoconazole and griseofulvin in dermatophytosis , 1985, The British journal of dermatology.

[37]  K. Ishak,et al.  Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. , 1984, Gastroenterology.

[38]  D. Bickers,et al.  Clinical pharmacology of skin disease , 1984 .

[39]  J. Wishart.  A DOUBLE BLIND TRIAL OF KETOCONAZOLE VERSUS GRISEOFULVIN TREATMENT FOR DERMATOPHYTE INFECTIONS , 1983, The Australasian journal of dermatology.

[40]  D. Stevens,et al.  Ketoconazole blocks testosterone synthesis. , 1982, Archives of internal medicine.

[41]  H. Blank.  Commentary: Treatment of Dermatomycoses With Griseofulvin , 1982 .

[42]  H. Blank.  "The treatment of dermatomycoses with orally administered griseofulvin" by Blank and Roth, March 1959. Commentary: Treatment of dermatomycoses with griseofulvin. , 1982, Archives of dermatology.

[43]  D. Stevens,et al.  Ketoconazole blocks adrenal steroid synthesis. , 1982, Annals of internal medicine.

[44]  F. W. Cox,et al.  Oral ketoconazole for dermatophyte infections. , 1982, Journal of the American Academy of Dermatology.

[45]  D. Feingold,et al.  Mechanisms of action of the antimycotic imidazoles. , 1981, The Journal of investigative dermatology.

[46]  J. Galgiani,et al.  Gynecomastia with Ketoconazole , 1981, Antimicrobial Agents and Chemotherapy.

[47]  H. Jones,et al.  Griseofulvin-resistant dermatophytosis correlates with in vitro resistance. , 1981, Archives of dermatology.

[48]  R. Legendre,et al.  A multi-center, double-blind comparison of ketoconazole and griseofulvin in the treatment of infections due to dermatophytes. , 1980, Reviews of infectious diseases.

[49]  O. Welsh,et al.  Treatment of dermatomycoses with ketoconazole. , 1980, Reviews of infectious diseases.

[50]  F. Odds,et al.  The activity in vitro and in vivo of a new imidazole antifungal, ketoconazole. , 1980, The Journal of antimicrobial chemotherapy.

[51]  J. Heeres,et al.  Antimycotic imidazoles. part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum antifungal agent. , 1979, Journal of medicinal chemistry.

[52]  L. Osment.  The many effects of griseofulvin. , 1969, The Alabama journal of medical sciences.

[53]  L. Ajello,et al.  Use of griseofulvin in office practice. , 1960, Archives of dermatology.

[54]  H. M. Robinson,et al.  In vitro resistance studies with griseofulvin. , 1960, Archives of dermatology.